Eton Pharmaceuticals, Inc. (ETON) Stock

Healthcare · Drug Manufacturers - Specialty & Generic · Member of Other US Stocks

Eton Pharmaceuticals, Inc. (ETON) closed at USD 52.88 on 2026-10-14, a change of +184.3 % over the past year, with a market capitalization of USD 1.47B.

Eton Pharmaceuticals, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Eton Pharmaceuticals, Inc. key figures

Previous close

USD 52.88 (2026-10-14)

1-year change

+184.3 %

Market cap

USD 1.47B

Enterprise value

USD 1.47B

P/E ratio (trailing)

135.08

P/E ratio (forward)

20.13

EPS (trailing)

0.38

EPS (forward)

2.55

PEG ratio

n/a

Price to book

31.17

Revenue growth

98.6 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

3.32

Employees

44

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Eton Pharmaceuticals, Inc. and compare it with other stocks.